var data={"title":"Calcipotriol (calcipotriene) and betamethasone: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Calcipotriol (calcipotriene) and betamethasone: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5733?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=calcipotriol-calcipotriene-and-betamethasone-patient-drug-information\" class=\"drug drug_patient\">see &quot;Calcipotriol (calcipotriene) and betamethasone: Patient drug information&quot;</a> and <a href=\"topic.htm?path=calcipotriol-calcipotriene-and-betamethasone-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Calcipotriol (calcipotriene) and betamethasone: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2524976\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Enstilar;</li>\n      <li>Taclonex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140722\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Dovobet;</li>\n      <li>Enstilar</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140733\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Corticosteroid, Topical;</li>\n      <li>\n        Vitamin D Analog</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140723\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Plaque psoriasis:</b> Topical: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Foam: Apply to affected area of skin once daily for up to 4 weeks (maximum dose: 60 g every 4 days).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gel [Canadian product]: Apply once daily to affected area(s) of body for up to 8 weeks or affected area(s) of scalp for up to 4 weeks. Maximum dose: 100 g/week (including other calcipotriol-containing products). Application to &gt;30% of body surface area (including scalp and body) is not recommended. Following discontinuation, therapy may be reinitiated for recurrence.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ointment: Apply to affected area of skin once daily for up to 4 weeks (maximum dose: 100 g/week). Application to &gt;30% of body surface area is not recommended. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Suspension: Apply to affected area of skin or scalp once daily for up to 8 weeks (maximum dose: 100 g/week)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26854742\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=calcipotriol-calcipotriene-and-betamethasone-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Calcipotriol (calcipotriene) and betamethasone: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Plaque psoriasis:</b> Children &ge;12 years and Adolescents: Topical:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ointment: Apply to affected area of skin once daily for up to 4 weeks (maximum dose: 60 g/week). Application to &gt;30% of body surface area is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Suspension: Apply to affected area of the scalp once daily for up to 8 weeks (maximum dose: 60 g/week).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140724\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140725\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gel [Canadian product]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild or moderate impairment: There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment: Use is contraindicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2525021\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gel [Canadian product]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild or moderate impairment: There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment: Use is contraindicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140713\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Foam, topical:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Enstilar: Calcipotriene 0.005% and betamethasone dipropionate 0.064% (60 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ointment, topical:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Taclonex: Calcipotriene 0.005% and betamethasone dipropionate 0.064% (60 g, 100 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Generic: Calcipotriene 0.005% and betamethasone dipropionate 0.064% (60 g, 100 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suspension, topical:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Taclonex: Calcipotriene 0.005% and betamethasone dipropionate 0.064% (60 g, 120 g) [contains castor oil]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2763809\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes: Ointment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10074488\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gel, topical:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dovobet: Calcipotriol 50 mcg/g and betamethasone 0.5 mg/g</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ointment, topical:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dovobet: Calcipotriol 50 mcg/g and betamethasone 0.5 mg/g</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2525022\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Wash hands before and after use. Do not apply to face, axillae, or groin or in the presence of preexisting skin atrophy at the treatment site; not for oral, ophthalmic, or intravaginal use. Avoid use of occlusive dressings over treated areas unless directed by a health care provider.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Foam: Shake before use. Rub into affected area gently.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gel [Canadian product]: Shake bottle before use. If using applicator, assemble per manufacturer instructions (refer to labeling) and then prime before initial use. After priming, the applicator delivers the product in 0.05 g actuations. If applying to the scalp, do not apply within 12 hours of chemical hair treatment. Do not shower/bathe or wash hair directly after use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ointment: Rub into affected area gently and completely.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suspension: Shake well before use. If applying to the scalp, do not apply within 12 hours of chemical hair treatment. Do not wash hair directly after use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140714\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Plaque psoriasis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Foam: Treatment of plaque psoriasis in patients 18 years and older.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gel [Canadian product]: Treatment of mild to moderate plaque psoriasis of the body or moderate to severe psoriasis of the scalp in patients 18 years and older.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ointment: Treatment of plaque psoriasis in patients 12 years and older.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suspension: Treatment of plaque psoriasis of the scalp (patients 12 years and older) and body (adults).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140709\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Also see individual agents.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%: Dermatologic: Pruritus (4% to 7%), psoriasis (2% to 3%), erythema (1% to 2%), skin atrophy (&le;2%), burning sensation of skin (1%), ecchymoses (1%), exfoliative dermatitis (1%), hand dermatosis (1%), skin depigmentation (1%), skin irritation (1%), folliculitis (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Acneiform eruption, acne vulgaris, application site irritation, application site pruritus, contact dermatitis, dermatitis, exacerbation of psoriasis, eye irritation, facial edema, HPA-axis suppression, hypercalcemia, hypercalciuria, hyperpigmentation, hypopigmentation, otitis externa, papular rash, psoriasis flare, psoriasis (rebound), pustular psoriasis, pustular rash, skin pain, skin rash, telangiectasia, urticaria, xeroderma</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140716\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed within the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in U.S. labeling): Hypersensitivity to calcipotriene, betamethasone, or any component of the formulation; viral (herpes simplex, varicella, vaccinia), fungal or bacterial infection of the skin; parasitic infections; tuberculosis of the skin; syphilitic skin infections; ophthalmic use; calcium metabolism disorders; perioral dermatitis; atrophic skin; striae atrophicae; fragility of skin veins; ichthyosis; acne vulgaris; acne rosacea; rosacea; ulcers; wounds; perianal and genital pruritus; guttate, erythrodermic and pustular psoriasis; severe hepatic disorders (gel only); severe renal insufficiency (gel only).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140707\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal suppression: Systemic absorption of topical corticosteroids may cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children, patients receiving high doses for prolonged period, use over large surface areas, under occlusion, or on altered skin barrier, and use in patients with hepatic failure. HPA axis suppression may lead to adrenal crisis and may occur during treatment or after withdrawal of treatment. If HPA axis suppression occurs, an attempt to withdraw the drug, reduce the application frequency, or substitute a less potent corticosteroid. HPA suppression is usually reversible; if glucocorticoid insufficiency occurs, supplemental systemic steroids may be needed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Contact dermatitis: Allergic contact dermatitis can occur; it is usually diagnosed by failure to heal rather than clinical exacerbation. Further evaluation (eg, patch testing) may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypercalcemia/hypercalciuria: Use with caution in patients with known or suspected disorders of calcium metabolism; may cause transient increases in serum and urinary calcium (reversible); if hypercalcemia or hypercalciuria occurs, discontinue treatment until levels return to normal. The effects on calcium metabolism following treatment durations of longer than 4 weeks (foam, ointment) or 8 weeks (suspension) have not been evaluated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Kaposi sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi sarcoma (case reports); if noted, discontinuation of therapy should be considered (Goedert, 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Local effects: Local adverse reactions may occur, including atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, and miliaria. These reactions are more likely to occur with occlusive use, prolonged use or use of higher potency corticosteroids; some reactions may be irreversible.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing's syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes mellitus: Hyperglycemia and unmasking of latent diabetes mellitus may result from systemic absorption of topical corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Photosensitivity: Avoid excessive exposure of treated skin to natural or artificial sunlight (eg, tanning booths, sun lamps) and phototherapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Skin infections: Use appropriate antibacterial or antifungal agents to treat concomitant skin infections; if infection persists, discontinue use of calcipotriene and betamethasone until infection has resolved.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Children may be at higher risk of systemic side effects due to a greater skin surface area:body weight ratio. Children may absorb proportionally larger amounts of corticosteroids after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity and delay weight gain; growth should be routinely monitored in pediatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Flammable contents: Foam contains flammable propellants. Avoid fire, flame, and smoking during and immediately following administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Do not use on the face, axillae, groin, or in the presence of preexisting skin atrophy at the treatment site. Not for oral, ophthalmic, or intravaginal use. Avoid exposure of suspension to the eyes; irritation may occur. Do not use occlusive dressings unless directed by a health care provider; discontinue use if irritation occurs.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298927\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6218753\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9406&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aluminum Hydroxide: Vitamin D Analogs may increase the serum concentration of Aluminum Hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Vitamin D Analogs may enhance the arrhythmogenic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sucralfate: Vitamin D Analogs may increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May enhance the hypercalcemic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin D Analogs: May enhance the adverse/toxic effect of other Vitamin D Analogs.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2524977\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2524978\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted with this topical combination. See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140717\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if calcipotriene or betamethasone are excreted into breast milk following topical application. The manufacturer recommends that caution be used if administered to breast-feeding women. Do not apply to the breast if breast-feeding. See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10074486\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Baseline serum calcium levels and then periodically during treatment in patients at risk for hypercalcemia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140706\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10074484\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3422202\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Foam</b> (Enstilar External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.005-0.064% (60 g): $1,184.51</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ointment</b> (Calcipotriene-Betameth Diprop External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.005-0.064% (60 g): $788.94</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ointment</b> (Taclonex External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.005-0.064% (60 g): $1,185.16</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Taclonex External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.005-0.064% (60 g): $1,184.51</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F140718\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Daivobet (AE, AU, BG, BH, BR, CH, CL, CN, CO, CZ, DE, DK, EC, EE, ES, FI, FR, HK, HU, ID, IL, IS, JO, KR, KW, LB, LT, LV, MT, MX, MY, NO, NZ, PH, PK, PL, PT, QA, RO, SA, SE, SG, SI, SK, TH, TW, VN);</li>\n      <li>Dovobet (BE, GB, GR, IE, IT, JP, NL);</li>\n      <li>Dyvon Plus (BD, LK);</li>\n      <li>Enstilar (IE);</li>\n      <li>Xamiol (AT, AU, BE, BG, CH, CN, CY, CZ, DE, DK, EE, ES, FI, FR, GR, HK, IL, IT, JO, KR, KW, LB, LT, LU, LV, MT, MY, NL, PH, PL, PT, QA, SE, SG, SI, SK, TH, TW, VN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Dovobet (calcipotriene/betamethasone dipropionate gel) [product monograph]. Thornhill, Ontario, Canada: LEO Pharma Inc; March 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dovobet (calcipotriene/betamethasone dipropionate ointment) [product monograph]. Thornhill, Ontario, Canada: LEO Pharma Inc; April 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Enstilar (calcipotriene/betamethasone dipropionate ointment) [prescribing information]. Madison, NJ: Leo Pharma Inc; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Enstilar (calcipotriene/betamethasone dipropionate ointment) [product monograph]. Thornhill, Ontario, Canada: LEO Pharma Inc; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goedert JJ, Vitale F, Lauria C, et al, &ldquo;Risk Factors for Classical Kaposi's Sarcoma,&rdquo; <i>J Natl Cancer Inst</i>, 2002, 94(22):1712-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcipotriol-calcipotriene-and-betamethasone-drug-information/abstract-text/12441327/pubmed\" target=\"_blank\" id=\"12441327\">12441327</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taclonex (calcipotriene and betamethasone dipropionate ointment) [prescribing information]. Madison, NJ: Leo Pharma Inc; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taclonex (calcipotriene and betamethasone dipropionate suspension) [prescribing information]. Madison, NJ: Leo Pharma Inc; June 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9406 Version 137.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F2524976\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F140722\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F140733\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F140723\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F26854742\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F140724\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F140725\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F2525021\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F140713\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F2763809\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F10074488\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F2525022\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F140714\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F140709\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F140716\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F140707\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298927\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6218753\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F2524977\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2524978\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F140717\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F10074486\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F140706\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F10074484\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F3422202\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F140718\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9406|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=calcipotriol-calcipotriene-and-betamethasone-patient-drug-information\" class=\"drug drug_patient\">Calcipotriol (calcipotriene) and betamethasone: Patient drug information</a></li><li><a href=\"topic.htm?path=calcipotriol-calcipotriene-and-betamethasone-pediatric-drug-information\" class=\"drug drug_pediatric\">Calcipotriol (calcipotriene) and betamethasone: Pediatric drug information</a></li></ul></div></div>","javascript":null}